Form 4: Avidity CFO Exits Equity Post-Novartis Merger

Avidity Biosciences' CFO, Michael F. MacLean, disposed of all common stock and stock options following the company's acquisition by Novartis AG.

Summary

• Michael F. MacLean, Chief Financial Officer of Avidity Biosciences, Inc., disposed of all his beneficial ownership in the company.
• The disposition occurred on February 27, 2026, as a direct result of the Agreement and Plan of Merger, dated October 25, 2025, with Novartis AG.
• MacLean disposed of 133,977 shares of common stock, which included shares issuable upon settlement of previously reported restricted stock units.
• He also disposed of 587,375 stock options across six different tranches, receiving a cash payment for the in-the-money value, calculated as the merger consideration of $72.00 per share minus the respective option exercise prices.
• Following these transactions, MacLean holds zero common stock and zero derivative securities in Avidity Biosciences, Inc.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive event for the reporting person, as it signifies a successful cash-out of equity holdings at a favorable merger price. For the company, it marks the completion of a significant acquisition.

Positives

• The CFO realized significant cash proceeds from the disposition of common stock and in-the-money stock options due to the merger.
• The merger consideration of $72.00 per share provided a substantial premium over the various option exercise prices, benefiting the option holder.

Negatives

• The CFO no longer holds any beneficial ownership in Avidity Biosciences, indicating a complete exit of his equity stake in the company post-merger.

Future Outlook

No specific future outlook or guidance is provided in this Form 4, as it reports a past transaction related to a completed merger.

Industry Context

StockSavvy.ai notes that this Form 4 filing confirms the finalization of the acquisition of Avidity Biosciences by Novartis AG, a significant event in the biotechnology and pharmaceutical sector. Such acquisitions often reflect strategic consolidation within the industry, with larger players like Novartis seeking to integrate promising assets or technologies from smaller, innovative firms like Avidity. The $72.00 per share merger consideration suggests a substantial valuation for Avidity, indicating the perceived value of its pipeline or technology by Novartis.

Comparison to Industry Standards

• This transaction represents a standard outcome for executive equity holdings during a corporate acquisition. The cash-out of in-the-money options at the merger consideration price is a common mechanism to settle executive compensation and equity incentives upon a change of control.
• For example, similar cash-out provisions were seen in the acquisition of Medivation by Pfizer ($81.50 per share) and the acquisition of Array BioPharma by Pfizer ($48 per share), where executive stock and options were converted to cash at the acquisition price.

Stakeholder Impact

• Shareholders: Existing shareholders of Avidity Biosciences would have received the $72.00 per share merger consideration.
• Employees: The future employment status of Avidity Biosciences employees, including the CFO, would be subject to the integration plans of Novartis AG.
• Management: The CFO has liquidated his equity stake, indicating the completion of his financial ties to the independent Avidity Biosciences.

Key Dates

Keywords

Avidity Biosciences, RNAM, Novartis AG, Merger, Form 4, Insider Transaction, Stock Options, Common Stock, Michael F. MacLean, CFO, Acquisition